The Comparison of Pre-diagnostic and Diagnostic Thrombocyte Levels in Pancreatic and Biliary Tract Cancers

Abstract

Aim The role of thrombocytes in tumor growth and metastatic spread was defined after the discovery of tumor fragments disseminated with thrombi brake off and embolization in distant body sites. Most cancers reported being related with thrombocytosis. In this study, we try to evaluate the variation of thrombocyte levels of biliary and pancreatic cancers in time to diagnosis. Material And Methods The patient records of Afyonkarahisar Health Sciences University Department of Medical Oncology between 2012 and 2018 were retrospectively analyzed. The patients who have 6 months or prior CBC before the diagnosis included in the study. Results A total number of 42 patients included in the study which was composed by 17 pancreatic, 17 biliary tract and 8 gallbladder adenocarcinomas after the complete evaluation of medical records. The mean (median) thrombocyte levels were 239000 (230000) and 260000 (251000) in pre-diagnostic and diagnostic groups respectively. The mean time between the prior blood test and diagnosis were 15.9 months. There was a statistically non-significant difference between pre-diagnostic and diagnostic thrombocyte levels. (p=0.08) The correlation was positive which determines thrombocyte levels increase with the time to diagnosis. When the thrombocyte levels categorized with the cut-off 400000 in the time of diagnosis and before diagnosis, there is a significant difference between groups. (p=0.04) Conclusion In this study, we found an elevation in the thrombocyte levels through the diagnosis of pancreaticobiliary tumors. The thrombocyte levels may be an indicator for this condition, but the alteration in normal ranges through the diagnosis makes it an unpractical marker.

Keywords

• Pancreatic Cancer
• Thrombocyte levels
• Early Diagnosis

Project Number

yok

The Comparison of Pre-diagnostic and Diagnostic Thrombocyte Levels in Pancreatic and Biliary Tract Cancers

Abstract

Abstract Aim The role of thrombocytes in tumor growth and metastatic spread was defined after the discovery of tumor fragments disseminated with thrombi brake off and embolization in distant body sites. Most cancers reported being related with thrombocytosis. In this study, we try to evaluate the variation of thrombocyte levels of biliary and pancreatic cancers in time to diagnosis. Material And Methods The patient records of Afyonkarahisar Health Sciences University Department of Medical Oncology between 2012 and 2018 were retrospectively analyzed. The patients who have 6 months or prior CBC before the diagnosis included in the study. Results A total number of 42 patients included in the study which was composed by 17 pancreatic, 17 biliary tract and 8 gallbladder adenocarcinomas after the complete evaluation of medical records. The mean (median) thrombocyte levels were 239000 (230000) and 260000 (251000) in pre-diagnostic and diagnostic groups respectively. The mean time between the prior blood test and diagnosis were 15.9 months. There was a statistically non-significant difference between pre-diagnostic and diagnostic thrombocyte levels. (p=0.08) The correlation was positive which determines thrombocyte levels increase with the time to diagnosis. When the thrombocyte levels categorized with the cut-off 400000 in the time of diagnosis and before diagnosis, there is a significant difference between groups. (p=0.04) Conclusion In this study, we found an elevation in the thrombocyte levels through the diagnosis of pancreaticobiliary tumors. The thrombocyte levels may be an indicator for this condition, but the alteration in normal ranges through the diagnosis makes it an unpractical marker.

Keywords

• Pancreatic Cancer
• Thrombocyte levels
• Early Diagnosis

Supporting Institution

yok

Project Number

yok

References

1. 1. Bizzozero, J. Ueber einen neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung - Untersuchungen. Arch. für Pathol. Anat. und Physiol. und für Klin. Med. 1882;90:261–332.
2. 2. Gücer F, Mosef F, Tamussino K, Reich O, Haas J, Arikan G, Petru E et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol. Oncol. 1998; 70(2):210–4.
3. 3. Beypınar İ, Demir H, Araz M., Beypınar D, Uysal M. The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment. J. Oncol. Sci. 2020;6:10–4
4. 4. Jemal A, Siegel R, Ward E, Yongping H, Xu J, Thun MJ. Cancer Statistics, 2009. CA. Cancer J. Clin. 2009;59(4): 225–49
5. 5. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. in American Journal of Surgery vol. 2005;189(3): 278–82
6. 6. Suzuki, K. et al. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepato-Gastroenterology vol. 2004;51:847–53 .
7. 7. Shazly TA, Al-Hussaini AK. Pediatric ocular injuries from airsoft toy guns. J. Pediatr. Ophthalmol. Strabismus 2012;49(1): 54–7
8. 8. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb. Haemost. 2003;90(4):570–6

9. 9. Hattori K, HeissigB, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97(11): 3354–60
10. 10. Hattori K, Dias S, Heissig B, Hackett NR,Lyden D, TatenoM, Hicklin DJ et al. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells. J. Exp. Med. 2001;193(9):1005-14
11. 11. Walker S, Hyde C, Hamilton W. Risk of breast cancer in symptomatic women in primary care: A case-control study using electronic records. Br. J. Gen. Pract. 2014;64: e788–e95 .
12. 12. Shephard E, Neal R, Rose P, Walter F, Hamilton WT. Clinical features of kidney cancer in primary care: A case-control study using primary care records. Br. J. Gen. Pract. 2013;63(9):e250-5
13. 13. Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005;60: 1059–65
14. 14. Hamilton W, Round A., Sharp D,Peters TJ. Clinical features of colorectal cancer before diagnosis: A population-based case-control study. Br. J. Cancer 2005;93(4): 399–405
15. 15. Stapley S, Peters TJ, Neal RD, Rose PW, Walter FM, Hamilton W. The risk of oesophago-gastric cancer in symptomatic patients in primary care: A large case-control study using electronic records. Br. J. Cancer 2013;108(1): 25–31 .
16. 16. Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton WT et. Clinical features of bladder cancer in primary care. Br. J. Gen. Pract. 2012;62(602):e598-604
17. 17. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: Population based case-control study. BMJ 2009;339:b2998
18. 18. Stapley S, Peters TJ, Neal RD, Rose PW, Walter FM, Hamilton W. The risk of pancreatic cancer in symptomatic patients in primary care: A large case-control study using electronic records. Br. J. Cancer 2012;106(12), 1940–44
19. 19. Walker S, Hyde C, Hamilton W. Risk of breast cancer in symptomatic women in primary care: A case-control study using electronic records. Br. J. Gen. Pract. (2014); 64(629):788-93
20. 20. Aggarwal A, Park J. Notes on searching in multidimensional monotone arrays. Annu. Symp. Found. Comput. Sci. 1988;497–512 (1988) doi:10.1109/sfcs.1988.21966.
21. 21. Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: A prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br. J. Gen. Pract. 2017;67(659): e405–e413
22. 22. Pedersen ML, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J. 1996;9(9): 1826–30
23. 23. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019;380(12): 1116–27